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ABSTRACT  
Purpose 
Evaluate MK-8242 in subjects with wild-type (WT) TP53 advanced solid tumors.  
Patients and Methods 
MK-8242 was administered p.o. BID, days 1-7 in 21-day cycles to determine. The recommended phase 2 
dose (RP2D) was determined based on safety/tolerability, pharmacokinetics (PK), pharmacodynamics 
(PD) in tumor/bloodand by mRNA expression of the p53 target PHLDA3. Other objectives were 
characterizing PK/PDpharmacodynamic (PD) relationship, correlation of biomarkers with response, and 
tumor response.   
Results 
47 subjects received MK-8242 across 8 doses ranging from 60-500 mg.  Initially, 6 subjects developed 
DLTs (G2/nausea at 120 mg; G3/fatigue at 250 mg; G2/nausea and G4/thrombocytopenia at 350 mg; 
G3/vomiting and G3/diarrhea at 500 mg). DLT criteria were revised to allow for management of 
gastrointestinal toxicities and dosing was resumed at 400 mg, and 4 additional DLTs were observed 
(G4/neutropenia and G4/thrombocytopenia at 400 mg; G4/thrombocytopenia [2 subjects] at 500 mg).  
Other drug-related G3-4 events included anemia, leukopenia, pancytopenia, nausea, hyperbilirubinemia, 
hypophosphatemia, and anorexia.  Based on safety/tolerability, PK, and PD, the RP2D was established at 
400 mg (i.e., 2 DLTs/15 evaluable subjects).  PK for 400 mg (Day 7) showed Cmax 3.07 µM, Tmax 3.0 hr, 
t1/2 6.6 hr, CL/F 28.9 L/hr, and Vd/F 274 L.  Blood PHLDA3 mRNA expression correlated with drug 
exposure (R2=0.68, P<0.001). In 41 subjects with post-baseline scans, 3 achieved PR (all with 
liposarcoma, at 250 mg, 400 mg and 500 mg), 31 showed SD, 8 had PD. In total, 27 subjects with 
liposarcoma had a median progression-free survival of 237 days.   
Conclusions 
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At the RP2D of 400 mg BID, MK-8242 activates the p53-pathway with an acceptable safety/tolerability 
profile.  The observed clinical activity (PR and prolonged PFS) provides impetus for further study of 
HDM2 inhibitors in liposarcoma. (ClinicalTrials.gov NCT01463696) 
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INTRODUCTION 
p53 protects cells from malignant transformation and is negatively regulated by the product of the 
Mouse Double Minute 2 (MDM2/HDM2) gene.1  Amplification of HDM2 amplification is observed in a 
variety of tumors including >90% of well-differentiated (WD) and dedifferentiated (DD) liposarcomas 
(LPS) as well as other sarcomas and carcinomas.2,3 Restoring p53 function through pharmacologic 
blockade of the HDM2:p53 protein-protein interaction may represent an anti-cancer therapeutic strategy.4  
Tumors that contain wild type (WT) p53 and also overexpress HDM2 represent ideal candidates for 
evaluating the clinical potential of HDM2:p53 protein-protein interaction inhibitors.   
An exploratory proof-of-mechanism trial demonstrated adequate safety/tolerability, p53 activation, 
anti-proliferative activity and preliminary anti-tumor efficacy of the investigational HDM2 inhibitor 
RG7112 in patients with chemotherapy-naïve LPS.5 Although promising, the findings were limited by  
small size and the overall short treatment duration. Thus, more definitive studies are needed to further 
assess the clinical potential of HDM2 inhibitors. 
MK-8242 (otherwise known asformerly SCH 900242) is a potent, orally bioavailable, small-
molecule inhibitor of the HDM2:p53 protein-protein interaction.6  This report describes a Phase I dose-
ranging study designed to establish the recommended phase 2 dose (RP2D) of MK-8242 based on 
safety/tolerability/pharmacokinetics (PK)/pharmacodynamics (PD) in adults with advanced solid tumors 
with WT (wild-type) TP53 gene.  
 
PATIENTS AND METHODS 
Study Design 
This multi-center, non-randomized, open-label, 2-part study (Merck & Co., Inc., Kenilworth, NJ; 
Protocol MK-8242-006; NCT01463696) was conducted at 4 centers (3 USA, 1 United Kingdom) between 
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December 2011 and March 2015.  This monotherapy study had 2 parts: dose escalation (Part 1; N=26) 
and RP2D dose confirmation/expansion (Part 2; N=21); only the dose escalation and dose confirmation 
cohorts were enrolled.  The study was terminated in June 2014 for non-safety reasons (i.e., change in 
oncology portfolio).  
Human exposure was determined from a previous Phase I trial conducted in healthy volunteers.  
The selection of the starting dose in this study was based on area under the curve (AUC) comparisons 
derived from the severely toxic dose in 10% of rodents (STD10) established in previous rat studies. The 
AUC at the rodent STD10 was 45.7 uM*hr; therefore, 1/10 of this exposure (4.57 uM*hr) was used to 
define the starting dose.  For 60 mg BID, considering the accumulation ratio of 1.44 (based on data at 160 
mg, assuming PK is time-independent), the AUC0-24hr at steady state was estimated to be 3.1 uM*hr; a 
value that is still less than the original estimated exposure of 4.57 uM*hr at 30 mg QD. Therefore, the 
starting dose was established at 60 mg BID. 
MK-8242 was dosed orally at doses from 60-500 mg BID on days 1-7 of a 21-day cycle until 
withdrawal criteria were met (Appendix Fig A1).  Single subjectssubject cohorts were initially treated 
with escalating MK-8242 doses. in increments of approximately 100%.7 WhenThe accelerated dose 
escalation continued until a subject experienced ≥1 dose-limiting toxicity (DLT) occurred), at a particular 
dose,which point escalation converted to a 3+3 design.8  EscalationIn the 3+3 portion, dose escalations 
were done at ~40%.  The starting dose in the 3+3 portion was 120 mg and therefore subsequent doses 
were 170, 250, 350 mg, etc.  Dose escalation continued until preliminary MTD identification based on 
toxicities observed during Cycle 1, defined as the highest dose at which <2/6 subjects experienced a DLT. 
Part 2 included a dose confirmation/expansion phase.8 Subjects 
All subjects provided written informed consent. The protocol was approved by Institutional 
Review Boards and/or Ethics Review Committees and conducted in accordance with the guidelines on 
Good Clinical Practice and ethical standards established by the Declaration of Helsinki. 
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Subjects 
 Eligible subjects included males and females, ≥18 years with histologically confirmed advanced 
solid tumors lacking effective standard therapies. Major inclusion/exclusion/withdrawal criteria are shown 
in Appendix Table A1. All patients were required to have histologically confirmed advanced solid 
tumors for which there were no effective standard therapy options.  Subjects in Part 2 or the 3+3 
escalation portion of Part 1 had tumors with confirmed WT TP53 gene (AmpliChip p53 Assay; Roche 
Molecular Systems, Pleasanton, CA).9,10    In addition, all patients had Eastern Cooperative Oncology 
Group (ECOG) performance status of 0- or 1, adequate organ function, and at least one measurable lesion 
as defined by RECIST 1.1.11  Patients with LPS who were enrolled in the dose confirmation phase were 
required to have confirmed WD or DD histology.  Subjects with any tumor type were eligible for dose 
confirmation phase, although the protocol required ≥15 subjects with WD/DD LPS.  Subjects 
discontinued for non-toxicity reasons were replaced if they did not complete the DLT evaluation period 
(Cycle 1).   
Dose delays ≤14 days were allowed for ≥Grade (G)3 adverse events (AEs), hematologic AEs 
lasting ≥1 week; thrombocytopenia with bleeding; neutropenia with infection or any non-hematologic AE.  
For ≥G3 neutropenia or thrombocytopenia, complete blood counts with differential and platelet counts 
were obtained every 3-4 days until resolution. 
 
 
Endpoints 
The primary endpoint was to identify DLTs and establish the RP2D. The sSecondary endpoints 
were objective radiological response rate as defined by RECIST v1.1 and PK/PD profile.11 Other 
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endpoints included AEs and laboratory safety assessments, progression-free survival (PFS; exploratory), 
and duration of response (exploratory).  
 
 
Assessments 
AEs were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for 
Adverse Events (CTCAE) v4.0.  DLTs were derived during the first cycle for each dose.  A DLT was any 
≥G3 drug-related hematological toxicity lasting ≥1 week; thrombocytopenia with bleeding; neutropenia 
with infection; or non-hematological toxicity requiring medical intervention/leading to 
hospitalization/persisting for ≥1 week.  Additional DLT criteria included missed doses (>20%) due to 
toxicity in Cycle 1; platelet transfusion with >1 week delay in starting Cycle 2.  The DLT criteria were 
modified by an amendment to the protocol which allowed for 72 hrs of maximal supportive care measures 
before Grade 3 nausea, vomiting, diarrhea, or dehydration were considered a DLT.  Prior to this 
amendment, any non-hematologic toxicity ≥ Grade 3 was considered a DLT; nausea and vomiting were 
excluded only if untreated.   
The preliminary MTD was the highest dose at which <33% of subjects experienced a DLT.  Dose 
escalation/Part 1 continued until an MTD was established then the dose confirmation/Part 2 began 
followed by response assessment. The RP2D was determined during the dose confirmation stage and was 
the dose at which 14 patients were enrolled with ≤ 5 DLTs.  
AEs were followed for ≥30 days following last dose of medication through Cycle 12.  After Cycle 
12, only serious AEs (SAEs) and events of clinical interest were reported.  Subjects discontinued due to 
AEs were followed until AE resolution/stabilization.  
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The PK profiles of MK-8242 and M16 (an MK-8242 metabolite with similar in vitro potency) 
were characterized in plasma samples collected on Days 1 and 7 of Cycle 1.  Plasma PK samples were 
collected  at 0, 0.5, 1, 2, 4, 6, 8, and 12hr after the firstmorning dose on Days 1 and 7. On Day 7, only one 
dose was given, with additional samples at 24 and 48hr post-dose. Sample handling and analysis were 
performed as described.6 The daily PK exposure goal of 25.0 uM*hr was established in a SJSA-1 
osteosarcoma xenograft murine model from the p21 (CDKN1A) mRNA induction level that resulted in 
significant tumor regression (data not shown).  The equivalent PK exposure goal in human was 
determined by linear regression of PK exposure against p21 mRNA expression in healthy humans, 
assuming the p21 exposureexpression was equally efficacious in human and mouse. 
 
Response Methodology 
CT scans of the chest, abdomen, and pelvis were performed within 28 days prior to the first dose 
and prior to every third cycle..  and cChanges in tumor size were evaluated by RECIST 1.1.11  
Confirmation of partial (PR) and complete responses by repeat imaging was performed ≥4 weeks after the 
initial response to ensure responses were not the result of measurement error.   
 
Pharmacodynamics 
 Optional pre-/post-treatment blood samples and tumor biopsies were collected to evaluate 
exploratory biomarkers. mRNA expression of the p53 target Pre-Homology-Like Domain, Family A, 
Member 3 (PHLDA3) was assessed as a potential biomarker of response.12  The PHLDA3 induction goal 
of 90 fold*hr (AUC0-12hr) relative to baseline was established from the same xenograft model.  The 
equivalent PHLDA3 induction goal in humans was determined by linear regression of PHLDA3 
exposureexpression against p21 exposureexpression in healthy humans. 
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Statistics 
 Safety/ tolerability were assessed by clinical review of relevant parameters including AEs.  
Toxicities were analyzed by dose/grade.  AEs were summarized as counts and frequencies by dose. The 
preliminary MTD was the highest dose at which <33% of subjects experienced a DLT.  Dose 
escalation/Part 1 continued until an MTD was established then the dose confirmation/Part 2 began 
followed by response assessment. The RP2D was determined during the dose confirmation stage and was 
the dose at which 14 patients were enrolled with ≤5 DLTs. [Refer to Appendix, Supplemental Methods 
for additional information.] 
 Response rates were summarized with point estimates and 95% exact confidence intervals (CI) 
using binomial distribution. PFS was the time from treatment to disease progression or death from any 
cause. PFS by tumor type (i.e., LPS) was estimated by Kaplan-Meier method.  
PFS was censored at the date of last tumor assessment for subjects: alive/progression-free; withdrawn 
consent; or lost to follow-up.  
For all PK parameters except Tmax, the geometric mean (GM) and coefficient of variation (median and 
range for Tmax) were calculated by dose. To assess dose proportionality, the power model at 90% CI was 
applied to log-transformed PK parameters.  Accumulation ratio was measured using AUC0-12hr. 
PHLDA3 AUC0-12hr was calculated as the AUC of relative genemRNA expression from 0-12h post-dose, 
corrected by the baseline value measured on Day 1 at 0 hr.  
 
Role of the Funding Source 
 
 Merck & Co., Inc. funded this study and was involved in study design/conduct/data collection/data 
analysis.   
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RESULTS 
Subject Characteristics 
At the time of trial termination, 48 subjects with advanced/refractory solid tumors were enrolled 
and 47 received treatment across 8 doses (Table 1).  Twenty-seven subjects (57%) had a diagnosis of LPS 
(predominantly DD), and all but 2 non-LPS subjects had a tumor with confirmed WT TP53. Of the 47 
treated patients, 27 (57.4%) were with LPS tumors at baseline: 9 (19.1%) and 17 (36.2%) were 
determined to have WD and DD histologies, respectively while 1 patient had an unknown LPS type. 
 
Subject Disposition 
Subjects were treated with MK-8242 orally BID at 60 (n=1), 120 (n=6), 170 (n=3), 250 (n=7), 300 
(n=3), 350 (n=6), 400 (n=15), or 500 mg (n=6).  Twelve subjects (26%) discontinued due to AEs 
(Appendix Table A2).  All AEs resolved by the end of the follow-up period/before last contact, except 
for 2 G3 events of thrombocytopenia (250 mg and 350 mg), 1 event of G4 neutropenia and 1 event of G3 
hypophosphatemia.  One subject with hyperbilirubinemia at treatment end was lost to follow-up before 
bilirubin normalized.  
 
AE Summary 
All subjects had ≥1 AE and 46/47 subjects experienced ≥1 drug-related AE. Common drug-related 
AEs included nausea (76.6%), fatigue (70.2%), decreased appetite (48.9%), diarrhea (48.9%), vomiting 
(38.3%), thrombocytopenia (34.0%), and neutropenia (31.9%). Also, 21/47 subjects (44.7%) experienced 
≥1 G3-4 drug-related AE, including 3 subjects each in the 250 mg (42.9%) and 350 mg (50.0%) groups, 
10 subjects in the 400 mg group (66.7%) and 5 subjects in the 500 mg group (83.3%)(%) (Appendix 
Table A3).  Grade 3-4 drug-related AEs included fatigue (10.6%), decreased appetite (2.1%), diarrhea 
(6.4%), vomiting (2.1%), thrombocytopenia (17.0%), and neutropenia (25.5%).  
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 Sixteen subjects (34.0%) experienced an SAE; 4/16 (8.5%) experienced drug-related SAEs. One 
subject in the 250 mg group experienced 2 drug-related G3 SAEs of fatigue and decreased appetite 
requiring hospitalization.  One subject in each of the 400 mg and 500 mg groups experienced drug-related 
SAEs of febrile neutropenia resulting in hospitalization.  One subject dosed at 500 mg experienced a 
drug-related SAE of vomiting not requiring hospitalization. There were no drug-related deaths or other 
drug-related G4 SAEs.   
 
DLT Summary  
Initially, 6 subjects developed DLTs (G2/nausea [missed >20% dose in Cycle 1] at 120 mg; 
G3/fatigue at 250 mg; G2/nausea [missed >20% dose in Cycle 1] and G4/thrombocytopenia at 350 mg; 
G3/vomiting and G3/diarrhea at 500 mg) under the original protocol-defined DLT criteria (Table 2).  The 
DLT criteria were subsequently revised via protocol amendment to permit medical management of 
gastrointestinal toxicities <72 hourshrs prior to considering such toxicities as DLTs.  Under the new 
criteria, 4 subjects developed an additional 5 DLTs (G4/neutropenia [n=1] and G4/thrombocytopenia 
[n=1] at 400 mg; G4/thrombocytopenia and G2/neutropenia [n=1 with 2 DLTs]; G4/thrombocytopenia 
[n=1] at 500 mg).  The 400 mg dose was identified as the protocol-defined RP2D, since only 2 DLTs 
were observed in 15 treated subjects (using the revised gastrointestinal DLT criteria). 
 
Pharmacokinetics/Pharmacodynamics 
The MK-8242 and M16 PK profiles are shown in Fig 1; Appendix Table A3.  The PK exposure 
goal of 25.0 uM*hr for MK-8242 (2xDay 7 geometric mean [GM]AUC0-12hr)  was exceeded for doses of 
350 mg (projected daily exposure of 26.2 µM*hr), 400 mg (33.0 µM*hr), and 500 mg (26.9 µM*hr), and 
additionally at 300 mg (25.2 µM*hr) for MK-8242+M16 (active metabolite). On Day 7, AUC0-12hr 
increased supra-proportionally versus dose for MK-8242 and MK-8242+M16 (Appendix Fig A2).  The 
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accumulation ratio from Day 1 to 7 was 1.04 for MK-8242 and 2.26 for M16.  The ratio of M16 to MK-
8242 exposure was 0.26 on Day 1, and 0.54 on Day 7.  Two subjects were co-administered 
dexamethasone as an antiemetic in the 500 mg group, and MK-8242 AUC0-12hr decreased 53% and 34%, 
respectively, from Day 1 to 7, presumably due to induction of CYP3A4. Use of dexamethasone was 
subsequently prohibited in this study.  
In the 300, 400, and 500 mg groups, mRNA expression of the p53 target gene PHLDA3 was well-
correlated with MK-8242 (R2=0.68; P<0.001) and MK-8242+M16 (R2=0.71; P<0.001) exposure (Fig 2).  
On Day 7, 12/15 patients met the PHLDA3 exposure target of 90 fold*hr including 11/13 patients 
receiving 400 mg. For patients with both valid PK and PD on Day 7, 12/14 exceeded both their PK/PD 
exposure goals. 
 
Tumor Response 
Post-baseline tumor measurements were obtained in 41 subjects; 6 did not have post-baseline 
scans due to discontinuation of dosing within 7 days of first dose (n=3 due to AE; n=1 progressive 
disease; n=1 protocol violation; n=1 withdrawal).  
Three PRs were observed in the 47 subjects who received ≥1 dose of MK-8242 (Fig 3).  ORR was 
6.4% for the entire study population (95% CI: 1.3, 17.5), and 11.1% in the 27 subjects with LPS (95% CI: 
2.4, 29.2).  ORR for subjects on the RP2D of 400 mg (n=1 pancreatic cancer; n=1 colorectal cancer; n=13 
LPS) was 6.7% (95% CI: 0.2, 32.0).  One subject (DD LPS, WT TP53) receiving 250 mg and 1 subject 
(WD LPS, WT TP53) receiving 400 mg achieved PRs following 102 days and 103 days of treatment, 
respectively. TheOne PR in the 250at 400 mg group was maintained for 64 days with the actual duration 
of response unknown because the subject discontinued treatment; no additional scans were 
performed.  The PR in the 400 mg group was maintained from Cycle 5 through Cycle 11 (at least 121 
days).  This subject remained in the study and received 17 cycles of treatment; no response assessment 
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data were collected after Cycle 11 and the total duration of response was unknown. subject remained on 
study for 17 cycles. In total, 5 LPS subjects (allwith WD LPS and WT TP53) treated at 400 mg had 
prolonged stable disease (n=4) or prolonged PR (n=1) ranging from 231 to 419 days while receiving ≥7 
cycles of treatment (n=4 completed 11 cycles).  One subject (WD LPS, WT TP53) in the 500 mg group .  
In addition, one subject with WD LPS had stable disease and discontinueduntil discontinuation from the 
study due to thrombocytopenia in Cycle 3/Day 56.  The patient was, but subsequently found to 
havedeveloped a confirmed PR outcome at Day 130, with subsequent confirmation by repeat  while not 
receiving additional treatments. Tumor progression rates for these subjects prior to study entry were not 
assessed because of the variability in imaging. This subject had not started other therapies, including 
chemotherapy, at the time the PR was detected frequency and prior treatments. 
     Kaplan-Meier curves of PFS for the overall treated population and the subgroup of subjects 
with LPS are shown in Fig 4.  Median PFS for the overall population was 3.4 months (95% CI: 3.2, 7.8), 
237 days7.8 months (95% CI: 993.3, ‘not estimable’) for subjects with LPS, and 2.9 months (95% CI:  
1.2, 3.3) for subjects without LPS.  The PFS for the DD LPS cohort was 5.5 months (95% CI:  2.1, ‘not 
estimable’) while PFS for the WD LPS cohort was not reached in this study. 
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DISCUSSION 
MK-8242 monotherapy had an acceptable safety and toxicity profile in patients with advanced 
solid tumors.  Six subjects developed  6 DLTs during Cycle 1 of treatment across the dosing range, 
including fatigue (250 mg), diarrhea (500 mg), nausea (120 mg and 350 mg), vomiting (500 mg), and 
thrombocytopenia (350 mg).  After revision of the DLT criteria to permit medical management of 
gastrointestinal-related toxicities prior to considering such AEs DLTs, 4subjects developed 5 DLTs of 
neutropenia and thrombocytopenia at 400 mg and 500 mg.  The protocol-defined RP2D was identified as 
400 mg since only 2 out of 15 subjects treated at this dose had DLTs under the new gastrointestinal-
management criteria.   
Overall, the observed pattern of gastrointestinal and hematologic toxicity was consistent with 
previous studies of MK-8242 and other HDM2 inhibitors.13,14 The most common drug-related AEs were 
<G3 and manageable; however, there was 1 drug-related SAE of vomiting (500 mg), 2 drug-related SAEs 
of febrile neutropenia (400 mg and 500 mg), and 2 G3 drug-related SAEs of decreased appetite and 
fatigue in one subject at the 250 mg dose.   Of note, there were no G5 toxicities.   
Exposure of MK-8242 and its active metabolite, M16, were supra-dose-proportional (greater than 
linear); the M16 accumulation ratio and ratio to MK-8242 indicate a significant role for this metabolite. 
Adequate PK/PD exposure for single agent activity, based on preclinical models, were achieved. The 
daily PK exposure target was exceeded for MK-8242 at 350 mg, 400 mg, and 500 mg doses; and at 300 
mg for MK-8242+M16. At the 300 mg, 400 mg, and 500 mg doses, PHLDA 3 expression exceeded target 
for 12/15 patients, and was well correlated with PK exposure. Taken together, these findings indicate that 
MK-8242 doses at 300 mg and above activate the p53 pathway, and corroborate the selection of the 400 
mg dose as the RP2D.    
This study demonstrated modest single-agent activity of MK-8242, specifically in LPS subjects 
with a confirmed WT TP53 gene.  Among 41 evaluable subjects, the best objective responses included 
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PRs in 3 subjects with LPS (2 WD,1 DD) dosed at 250 mg, 400 mg, and 500 mg.  The subjects in the 250 
mg and 400 mg groups maintained PRs through 64 and 121 days, respectively.  The subject in the 500 mg 
group achieved a confirmed PR 74 days after discontinuing from the study in Cycle 3.  This patient was 
not taking chemotherapy at the time of the PR outcome. Additionally, 5 subjects (LPS receiving 400 mg) 
had prolonged stable disease for ≥7 cycles.   
The median PFS for patients with LPS was 237 days (approximately 34 weeks). Although7.8 
months (approximately 34 weeks or 237 days); however, considering that one third of patients with LPS 
had WD tumors for which the median PFS was not reached, it is difficult to determine whether this 
prolonged disease control rate is an effect of MK-8242 or reflects the potentially indolent nature of this 
tumor subtype. Although pre-study progression rates were not available for reference, the median PFS of 
patients with DD LPS (5.5 months) suggests that MK-8242 treatment contributed at least in part to 
prolonged disease control.  Acknowledging that direct comparisons cannot be made across studies 
because of variations in study designs and patient populations, it is notable that the median PFS for LPS 
patients with progressive WD or DDLPS in two phase 2 studies of a CDK4 inhibitor was only 18 weeks 
(approximately 126 days).15-18  The median PFS rates seen in these prior studies of CDK inhibitors were 
generally similar to those seen in two recent phase 3 studies of eribulin versus dacarbazine (4.2 versus 1.5 
months) and trabectedin versus dacarbazine (2.6 months for both groups).  Taken together, the results of 
this MK-8242 study confirm and extend those of a prior study5 demonstrating preliminary evidence of 
anti-tumor activity of HDM2:p53 protein-protein inhibitors in LPS patients.   
Although the preclinical target exposure was reached and there was induction of expression of 
PHLD3A, a biomarker of p53 transcriptional activity, the degree of clinical activity was less than 
expected based on preclinical models, particularly in terms of tumor regression.   This discordance may be 
due to any of many factors: for example, prior treatment of the study population may have selected for a 
more resistant disease state; intratumoral exposure may be less than exposure determined by plasma 
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assays; and although the dose and schedule may have permitted induction of p53 transcriptional activity, 
it may have been insufficient for p53-mediated induction of apoptosis.  Furthermore, it is unclear if MK-
8242 may show greater efficacy when administered in combination with other traditional 
chemotherapeutic agents. 
In summary, evidence of single-agent clinical efficacy was observed in LPS patients.  Using a 7 
day-on/14 day-off dosing schedule, MK-8242 was generally safe at doses up to 400 mg and the RP2D 
was 400 mg BID based on the observed safety/tolerability, PK and PD profiles.  The potential for 
gastrointestinal and hematological toxicities, particularly neutropenia and thrombocytopenia, should be 
considered when designing future clinical studies.  Tolerance and activity of MK-8242 in combination 
with conventional chemotherapeutic agents or following alterations in monotherapy schedule including 
lower doses/longer term or higher doses/shorter term are important future studies needed to more 
thoroughly evaluate the potential clinical activity and safety/tolerability of HDM2 inhibitors in patients 
with advanced solid tumors.  Particularly important for combination therapy studies is careful attention to 
hematologic toxicities since similar effects are elicited by standard chemotherapeutic agents and may be 
exacerbated when administered together with HDM2 inhibitors.   The results of this study should aid 
improved trial design for future studies. 
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Table 1.  Baseline demographics and disease characteristics in treated population 
  n (%) 
Number treated  47 
Gender (male)   28 (59.6%) 
Age (years) - mean ± SD  61.6 ± 10.6 
ECOG performance status    
     0  23 (48.9%) 
     1  24 (51.1%) 
Race    
     White  44 (93.6%) 
     Black or African 
American 
3 (6.4%) 
TP53 Mutation status   
     Wild-Type  45 (95.7%) 
     Unknown  2 (4.3%) 
Primary Diagnosis   
     Liposarcoma  27 (57.4%) 
          WD  9 (19.1%) 
          DDa†  17 (36.2%) 
          Unknown  1 (2.1%) 
     Other Tumorb§  20 (42.6%) 
DD= dedifferentiated; ECOG= Eastern Cooperative Oncology Group; WD = well differentiated 
a†Includes 1 subject with ‘DD liposarcoma/sarcomatoid renal cell carcinoma’ and 1 subject with ‘DD/WD liposarcoma’ diagnoses at baseline 
b§Includes 2 subjects with unknown tumor diagnoses at baseline 
   
Formatted: Superscript
Formatted: Superscript
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Table 2.  Number (%) of subjects with DLTsa summarized by Grade and MK-8242 dose 
MK-8242 dose 60 mg BID 
n=1 
120 mg 
BID 
n=6 
170 mg 
BID 
n=3 
250 mg 
BID 
n=7 
300 mg 
BID 
n=3 
350 mg 
BID 
n=6 
400 mg 
BID 
n=15 
500 mg 
BID 
n=6 
Total no. 
subjects 
with DLTs 
within 
each 
Grade, 
across all 
dose levels 
N=47 
Grade 1 0 0 0 0 0 0 0 0 0 
Grade 2 0 1 (16.7%) 0 0 0 1 (16.7%) 0 1 (16.7%) 3 (6.4%) 
Grade 3 0 0 0 1 (14.3%) 0 0 0 2 (33.3%) 3 (6.4%) 
Grade 4 0 0 0 0 0 1 (16.7%) 2 (13.3%) 2 (33.3%) 5 (10.6%) 
Grade 5 0 0 0 0 0 0 0 0 0 
Total no. of subjects with 
DLTs at each dose level, across 
all Grade 
0 1 (16.7%) 0 1 (14.3%) 0 2 (33.3%)  2 (13.3%)b 5 (83.3%)b 11 
DLT= dose limiting toxicity; Grade= toxicity grade based on CTCAE version 4.0 
aOnly the highest reported grade for a given DLT is counted for each individual subject 
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bThere were 2 DLTs observed under the revised criteria:  2 DLTs at 400 mg and 2 DLTs at 500 mg
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Figure Legends 
 
Fig 1.  Geometric mean plasma concentration-time curves for MK-8242 and metabolite M16 following 
treatment on Days 1 and 7 of Cycle 1.  Only one dose was administered on Day 7 to support characterization of 
pharmacokinetics (PK). 
 
Fig 2.  Individual exposure relationships between plasma pharmacokinetics (PK) and PHLDA3 mRNA 
expression in plasma  on Day 7 for MK-8242 and MK-8242+M16.  Linear model fits (black line) and 95% CI 
(shaded gray) are shown for illustration purposes, only.  Vertical and horizontal dotted lines represent the pre-
clinically established exposure targets for PK and pharmacodynamics (PD), respectively. 
 
Fig 3.  Treatment response:  Swimmer plot for the 47 treated patients, with time since therapy (months) shown 
for each patient.  Blue line indicates LPS patient; orange line indicates non-LPS tumor types. Stable disease, 
partial response and progressive disease are denoted by filled pink, green, and red dots.  The last completed 
cycle of treatment prior to discontinuation is noted in red font. The open blue circles denote discontinuation of 
treatment.  The dose level for each subject and type of LPS (WW/DD) is juxtaposed next to the relevant bars.   
 
Fig 4.  Kaplan-Meier estimates of progression-free survival (PFS) presented for the overall population and the 
subgroup of patients with LPS.  The inset shows Kaplan-Meier estimates of PFS for the WD and DD LPS 
cohorts. 
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Table legends 
 
Table 1.  Baseline demographics and disease characteristics 
 
Table 2.  Number (%) of subjects with DLTsa summarized by Grade and MK-8242 dose 
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Fig  1.  Geometric mean plasma concentration-time curves for MK-8242 and metabolite M16 following 
treatment on Days 1 and 7 of Cycle 1.  Only one dose was administered on Day 7 to support characterization of 
pharmacokinetics (PK). 
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Fig 2.  Individual exposure relationships between plasma pharmacokinetics (PK) and PHLDA3 mRNA 
expression in plasma on Day 7 for MK-8242 and MK-8242+M16.  Linear model fits (black line) and 95% CI 
(shaded gray) are shown for illustration purposes, only.  Vertical and horizontal dotted lines represent the pre-
clinically established exposure targets for PK and pharmacodynamics (PD), respectively. 
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Fig 3.  Treatment response:  Swimmer plot for the 47 treated patients, with time since therapy (months) shown 
for each patient.  Blue line indicates LPS patient; orange line indicates non-LPS tumor types. Stable disease, 
partial response and progressive disease are denoted by filled pink, green, and red dots.  The last completed 
cycle of treatment prior to discontinuation is noted in red font. The open blue circles denote discontinuation of 
treatment.  The dose level for each subject and type of LPS (WW/DD) is juxtaposed next to the relevant bars.   
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Fig 4.  Kaplan-Meier estimates of progression-free survival (PFS) presented for the overall population and the 
subgroup of patients with LPS.  The inset shows Kaplan-Meier estimates of PFS for the WD and DD LPS 
cohorts. 
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Data Supplement (online only) Appendix 
 
Supplemental Methods 
 
Subjects 
Dose delays ≤14 days were allowed for ≥Grade (G)3 adverse events (AEs), hematologic AEs lasting ≥1 
week; thrombocytopenia with bleeding; neutropenia with infection or any non-hematologic AE.  For ≥G3 
neutropenia or thrombocytopenia, complete blood counts with differential and platelet counts were obtained 
every 3-4 days until resolution. 
 
Endpoints 
Other endpoints included AEs and laboratory safety assessments, progression-free survival (PFS; 
exploratory), and duration of response (exploratory).  
 
Assessments 
Additional DLT criteria included missed doses (>20%) due to toxicity in Cycle 1; platelet transfusion 
with >1 week delay in starting Cycle 2.  The daily PK exposure goal of 25.0 uM*hr was established in a SJSA-1 
osteosarcoma xenograft murine model from the p21 (CDKN1A) mRNA induction level that resulted in 
significant tumor regression (data not shown).  The equivalent PK exposure goal in human was determined by 
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linear regression of PK exposure against p21 mRNA expression in healthy humans, assuming the p21 
expression was equally efficacious in human and mouse. 
 
Response Methodology 
Confirmation of partial (PR) and complete responses by repeat imaging was performed ≥4 weeks after 
the initial response to ensure responses were not the result of measurement error.   
 
Pharmacodynamics 
 The PHLDA3 induction goal of 90 fold*hr (AUC0-12hr) relative to baseline was established from 
the same xenograft model.  The equivalent PHLDA3 induction goal in humans was determined by linear 
regression of PHLDA3 expression against p21 expression in healthy humans. 
 
Statistics 
 PFS was censored at the date of last tumor assessment for subjects: alive/progression-free; withdrawn 
consent; or lost to follow-up.  
For all PK parameters except Tmax, the geometric mean (GM) and coefficient of variation (median and 
range for Tmax) were calculated by dose. To assess dose proportionality, the power model at 90% CI was applied 
to log-transformed PK parameters.  Accumulation ratio was measured using AUC0-12hr. 
PHLDA3 AUC0-12hr was calculated as the AUC of relative mRNA expression from 0-12hr post-dose, 
corrected by the baseline value measured on Day 1 at 0 hr.  
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Appendix Figures and Tables 
 
Appendix Fig A1. Study diagram  *A cycle is defined as 21 days in length and includes 7 days of BID dosing of 
MK-8242 taken on Days 1-7. Cycle 1 Day 7 will only include a morning dose to accommodate PK sampling. 
**During the study, CT scans for all known sites of disease observed prior to treatment with MK-8242 were 
performed prior to every third cycle between treatment days 15 and 21. 
†Cycle 1, Day 7 only included a morning dose to accommodate PK sampling 
 
Appendix Fig A2. Geometric mean exposure versus dose for MK-8242 and MK-8242+M16 following treatment 
on Day 7 of Cycle 1.  Solid lines represent the power model fit, and shaded regions represent the 95% CI. 
 
Appendix Table A1.   Inclusion/exclusion and study withdrawal criteria. 
 
Appnedix Table A2.  Listing of subjects who discontinued from the study due to adverse events  
 
Appendix Table A3. Number (%) of subjects with drug-related Grade 3-4 AEs presented by MK-8242 dose 
 
Appendix Table A4.  Summary of preliminary pharmacokinetic (PK) parameters of MK-8242 during 60 – 500 
mg doses of MK-8242 BID for 7 days. 
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 Fig A1. Study design 
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Fig  A2.  Geometric mean exposure versus dose for MK‐8242 and MK‐8242+M16 following treatment on Day 7 of Cycle 
1.  Solid lines represent the power model fit, and shaded regions represent the 95% CI. 
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Table A1.  Inclusion/exclusion and study withdrawal criteria. 
Additional Inclusion Criteria Significant Exclusion Criteria Study Withdrawal Criteria 
ECOG ≤1 untreated leptomeningeal metastasis, 
or metastatic CNS disease 
failure to comply with the study 
requirements 
dequate organ function as assessed 
within 14 days of Cycle 1 
history of myocardial infarction 
within 1 year of enrollment 
disease recurrence or progression 
hemoglobin ≥9.0 g/dL Hepatitis dose delay >2 weeks 
absolute neutrophil count ≥1.5x 
109/L 
HIV positive intercurrent illness 
platelet count ≥100x 109/L  unacceptable AEs not manageable 
by symptomatic therapy 
creatinine <1.5 ULN or calculated 
creatinine clearance ≥60 mL/min 
 serious or life-threatening AE 
total bilirubin <1.5 ULN/direct 
bilirubin ≤ULN 
  
aspartate aminotransferase/serum 
glutamic-oxalecetic transaminase 
and alanine aminotransferase/serum 
pyruvic transaminases ≤3x ULN 
(≤5x ULN in the presence of liver 
metastases) 
  
alkaline phosphatase <2.5x ULN 
(with no bone metastases) 
  
AE= adverse experiences; CNS= central nervous system; ECOG= Eastern Cooperative Oncology Group 
performance status; HIV= human immunodeficiency virus; ULN= Upper limit of normal 
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Table A2.  Listing of subjects who discontinued from the study due to adverse events 
MK-8242 dose Number of Subjects Who Discontinued Due 
to AE  
Reason for Discontinuation 
(Grade/Treatment Cycle) 
120 mg BID N=2 Nausea G1/Cycle 1 
Nausea G2/Cycle 4 
250 mg BID N=1 Thrombocytopenia G3/Cycle 4 
350 mg BID N=4 Nausea G2/Cycle 1 
Fatigue G2/Cycle 1 
Pulmonary embolism G3/Cycle 4 
Thrombocytopenia G3/Cycle 8 
400 mg BID N=3 Thrombocytopenia G2/Cycle 7  
Hyperbilirubinaemia G3/Cycle 6 
Neutropenia G4/Cycle 1 
500 mg BID N=2 Decreased appetite G2, Nausea G2, 
Vomiting G3/Cycle 2 
Hypophosphatemia G3/Cycle 5 
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Table A3.  Number (%) of subjects with drug-related Grade 3-4 AEsa presented by MK-8242 dose 
MK-8242 dose 60 mg BID 
n=1 
120 mg 
BID 
n=6 
170 mg 
BID 
n=3 
250 mg 
BID 
n=7 
300 mg 
BID 
n=3 
350 mg 
BID 
n=6 
400 mg 
BID 
n=15 
500 mg 
BID 
n=6 
Total 
N=47 
Subjects with ≥1 drug-related 
AE, Grade 3-4 
0 0 0 3 (42.9%) 0 3 (50.0%) 10 (66.7%) 5 (83.3%) 21 (44.7%) 
Blood and lymphatic 
system disorders 
0 0 0 1 (14.3%) 0 2 (33.3%) 9 (60.0%) 2 (33.3%) 14 (29.8%) 
Anemia 0 0 0 0 0 1 (16.7%) 0 0 1 (2.1%) 
Febrile neutropenia 0 0 0 0 0 0 1 (6.7%) 1 (16.7%) 2 (4.3%) 
Leukopenia 0 0 0 0 0 0 1 (6.7%) 0 1 (2.1%) 
Neutropeniab 0 0 0 0 0 1 (16.7%) 8 (53.3%) 0 9 (19.1%) 
Pancytopenia 0 0 0 0 0 0 0 1 (16.7%) 1 (2.1%) 
Thrombocytopeniab 0 0 0 1 (14.3%) 0 2 (33.3%) 3 (20.0%) 1 (16.7%) 7 (14.9%) 
Gastrointestinal disorders 0 0 0 0 0 0 1 (6.7%) 3 (50.0%) 4 (8.5%) 
Diarrhea 0 0 0 0 0 0 1 (6.7%) 2 (33.3%) 3 (6.4%) 
Vomiting 0 0 0 0 0 0 0 1 (16.7%) 1 (2.1%) 
General disorders and 
administration site 
conditions 
0 0 0 2 (28.6%) 0 1 (16.7%) 1 (6.7%) 1 (16.7%) 5 (10.6%) 
Fatigue 0 0 0 2 (28.6%) 0 1 (16.7%) 1 (6.7%) 1 (16.7%) 5 (10.6%) 
Investigations 0 0 0 0 0 1 (16.7%) 0 2 (33.3%) 3 (6.4%) 
Neutrophil count decreasedb 0 0 0 0 0 0 0 1 (16.7%) 1 (2.1%) 
Platelet count decreasedb 0 0 0 0 0 0 0 1 (16.7%) 1 (2.1%) 
White blood cell count 0 0 0 0 0 1 (16.7%) 0 1 (16.7%) 2 (4.3%) 
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decreased 
Metabolism and nutrition 
disorders 
0 0 0 1 (14.3%) 0 0 0 1 (16.7%) 2 (4.3%) 
Decreased appetite 0 0 0 1 (14.3%) 0 0 0 0 1 (2.1%) 
Hypophosphataemia 0 0 0 0 0 0 0 1 (16.7%) 1 (2.1%) 
aEvery subject is counted a single time for each applicable row and column 
bThe preferred terms of ‘Febrile neutropenia’. ‘Neutrophil count decreased’ and ‘Neutropenia’ identify the same AE but code to different SOC categories; the preferred terms of 
‘Platelet count decreased’ and ‘Thrombocytopenia’ identify the same AE but code to different SOC categories. 
AE=adverse event 
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Table A4. Summary of pharmacokinetic (PK) parameters of MK-8242 during 60-500 mg doses of MK-8242 
administered twice daily (BID) for 7 days. 
Dose N Day Cmax (nM)a 
Tmax 
(h)b 
AUC0-
12h 
(nM*h)a
t1/2 
(h)a 
CL/F 
(L/h)a 
Vd/F  
(L)a 
60 mg 
BID 
1 1 162 2.03          548 -- -- -- 
1 7 150 1.98          706 2.59 101 377 
120 mg 
BID 
5 1 402 (101.2) 
2.07 
(1.95-6.08) 
1820 
(51.2)c 
2.57 
(42.4)d 
59.3 
(26.2)d 
220 
(22.5)d 
5 7 551 
(90.1) 
4.00         
(1.88-6.08) 
2450 
(57.9) 
3.91 
(140.5)e 
58.3 
(57.9) 
191 
(259.0)e 
170 mg 
BID 
3 1 813 (208.7) 
4.30         
(2.00-6.00) 11000
f 2.97f 17.2f 74.0f 
3 7 
1680 
(30.2) 
2.00          
(2.00-4.00) 
7190 
(24.7) 
5.05 
(10.8) 
28.1  
(24.7) 
205 
(23.1) 
250 mg 
BID 
6 1 
1210 
(80.4) 
4.00          
(2.00-4.27) 
5550 
(100.1)d 
5.92 
(121.6)d 
34.8 
(121.7)d 
297 
(114.4)d 
6 7 
1030 
(133.7) 
3.23          
(2.00-11.97) 
6710 
(130.9) 
4.40 
(20.6)c 
44.4 
(130.9) 
229 
(52.6)c 
300 mg 
BID 
3 1 
1320 
(33.4) 
2.18          
(2.00 -2.23) 
5020  
(45.4) 
3.12 
(73.8) 
63.2  
(55.0) 
285 
(49.2) 
3 7 
1720 
(89.7) 
2.00          
(2.00-2.00) 
8720 
(65.1) 
7.90 
(33.0) 
41.0 
(65.1) 
467 
(32.1) 
350 mg 
BID 
6 1 
1510 
(166.2) 
4.04          
(2.00 -4.08) 
6940 
(110.7)e 
2.40 
(0.2)e 
56.0 
(106.3)e 
194 
(106.0)e 
5 7 
1930 
(52.4) 
4.00          
(2.00-5.97) 
13100 
(70.2)c 
5.48 
(49.1)c 
31.9 
(70.2)c 
252 
(78.9)c 
400 mg 
BID 
14 1 
3820 
(39.4) 
2.00          
(1.00-11.47) 
16800 
(45.3)g 
3.65 
(25.1)g 
24.9 
(48.9)g 
131 
(44.5)g 
12 7 
3070 
(38.7) 
3.03          
(2.00-6.92) 
16500 
(41.2) 
6.57 
(41.7) 
28.9 
(41.3) 
274 
(60.5) 
500 mg 
BID 
6 1 
4240 
(45.5) 
3.04          
(2.00-8.00) 
24100 
(46.0)c 
3.74 
(47.2)c 
20.8 
(54.0)c 
112 
(50.1)c 
3 7 
1800 
(63.0) 
2.08          
(2.00-4.00) 
13400 
(77.8) 
5.92 
(22.7) 
44.3 
(77.8) 
378 
(53.6) 
aGeometric mean (%CV);  bMedian (min - max); cN=4; dN=3; eN=2; fN=1; gN=12 
 
 
 
 
